{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-065926","form_type":"8-K","ticker":"APGE","cik":"0001974640","company_name":"Apogee Therapeutics, Inc.","filed_at":"2025-07-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.734040+00:00","generated_at":"2026-05-18T09:21:56.586412+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Apogee: Phase 2 APG777 hits all endpoints; EASI-75 66.9% (42.5% placebo-adjusted), safety favorable","bullets":["APEX Part A met primary endpoint: 71% mean EASI reduction vs 33.8% placebo (p<0.001).","EASI-75 achieved by 66.9% of APG777 patients vs 24.6% placebo (p<0.001); highest of any biologic in global study.","Rapid itch relief: 50.7% reduction in Itch NRS at Week 1 (p<0.01). Safety well-tolerated, no injection site reactions.","Exposure-response: top quartiles had 83-89% EASI-75; Part B testing higher dose, readout mid-2026.","52-week maintenance data expected 1H 2026; APG279 Phase 1b vs DUPIXENT dosed, readout 2H 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-065926","json":"https://secwatch.observer/filing/0001104659-25-065926.json","markdown":"https://secwatch.observer/filing/0001104659-25-065926.md","text":"https://secwatch.observer/filing/0001104659-25-065926.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1974640/000110465925065926/0001104659-25-065926-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1974640/000110465925065926/tm2519512d2_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T09:21:56.586412+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}